Filing Details
- Accession Number:
- 0001415889-25-020605
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-07-30 17:57:52
- Reporting Period:
- 2025-07-28
- Filing Date:
- 2025-07-30
- Accepted Time:
- 2025-07-30 17:57:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1672619 | Enliven Therapeutics Inc. | ELVN | Pharmaceutical Preparations (2834) | 811523849 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1882764 | Benjamin Hohl | C/O Enliven Therapeutics, Inc. 6200 Lookout Road Boulder CO 80301 | Chief Financial Officer | No | No | No | No |
Transaction Summary
| Sold: | 3,250 shares | Avg. Price: $20.46 | Total Value: $66,503.76 |
| Number of Shares After Transactions: | 23,000 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-07-28 | 3,250 | $2.48 | 26,250 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-07-28 | 3,185 | $20.45 | 23,065 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-07-28 | 65 | $21.30 | 23,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2025-07-28 | 3,250 | $0.00 | 3,250 | $2.48 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 111,556 | 2031-08-02 | No | 4 | M | Direct |
Footnotes
- The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
- This transaction was executed in multiple trades at prices ranging from $20.09 to $21.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $21.1377 to $21.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- All of the shares subject to this option are fully vested and exercisable as of the date hereof.
Billionaire Hedge Funds
